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Abstract: The known occurrence of pharmaceuticals in the built and natural water 
environment, including in drinking water supplies, continues to raise concerns over 
inadvertent exposures and associated potential health risks in humans and aquatic 
organisms. At the same time, the number and concentrations of new and existing 
pharmaceuticals in the water environment are destined to increase further in the future as a 
result of increased consumption of pharmaceuticals by a growing and aging population and 
ongoing measures to decrease per-capita water consumption. This review examines the 
occurrence and movement of pharmaceuticals in the built and natural water environment, 
with special emphasis on contamination of the drinking water supply, and opportunities for 
sustainable pollution control. We surveyed peer-reviewed publications dealing with 
quantitative measurements of pharmaceuticals in U.S. drinking water, surface water, 
groundwater, raw and treated wastewater as well as municipal biosolids. Pharmaceuticals 
have been observed to reenter the built water environment contained in raw drinking water, 
and they remain detectable in finished drinking water at concentrations in the ng/L to μg/L 
range. The greatest promises for minimizing pharmaceutical contamination include source 
control (for example, inputs from intentional flushing of medications for safe disposal, and 
sewer overflows), and improving efficiency of treatment facilities. 
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1. Introduction 
Intended uses of pharmaceuticals in humans and animals are plentiful and include the prevention, 
diagnosis, and therapy of diseases as well as cosmetic and lifestyle purposes [1]. In recent years, 
however, their occurrence in the environment has raised concerns, both nationally and internationally, 
regarding implied risks posed to aquatic and terrestrial life forms, including humans [2–7]. In the United 
States (U.S.), pharmaceuticals have been found to occur throughout the water environment [8–13], 
including the drinking water supply [14–18]. Whereas the perceived and actual risks of trace levels of 
pharmaceuticals in drinking water is a topic of ongoing discussion, this review concentrates on the 
sources and pathways of water contamination in the U.S. to assess our understanding of the occurrence 
of pharmaceuticals in U.S. drinking water, and to identify opportunities for pollution control. 
Environmental exposures of humans and aquatic organisms to pharmaceuticals have been  
reported [19–25] and the associated risks evaluated [17,26–28]. For example, human health impacts 
were assessed from exposure to pharmaceutically active compounds in drinking water [14–18] and 
edible fish [19–25]. Additionally, specific modes of action of pharmaceuticals have been evaluated in 
humans and mammals [29], including an analysis of metabolism and excretion by humans [30]. 
Overall, these studies conclude that, based on current knowledge, the presence of trace levels of 
pharmaceuticals poses negligible or only minor risks to humans. Exposure of aquatic organisms also is 
well established [31] and extends into coastal waters, as illustrated by reports on the antibacterial 
chemical triclosan, that was measured in blood plasma of wild bottlenose dolphins (Tursiopstruncatus) 
(0.025–0.11 ng/g wet weight), and in estuarine surface water samples (4.9–14 ng/L) [20]. 
Concerning the built (man-made) water environment, a significant volume of literature explored the 
performance of treatment plants for the removal of pharmaceuticals from raw wastewater  
(sewage) [32–36] and from raw drinking water [37–39]. Additional studies investigated various 
strategies for efficient removal and transformation of pharmaceuticals using advanced treatment 
employing processes of chemical [32,40–43], biological [44–47] and physical nature [48,49]. Since not 
all pharmaceuticals present in sewage are the result of intentional intake, metabolism and excretion, 
some researchers have investigated the composition of wastewaters from the pharmaceutical  
industry [50], and healthcare facilities [51], as well as the importance of disposal of unwanted or 
leftover pharmaceuticals into sanitary sewers [1,2,52–56]. 
The aforementioned reviews and articles carry valuable information and discussion on occurrences, 
treatment efficiencies, and risk assessments of pharmaceuticals in the environment. However, our 
focus in this review is to specifically examine the occurrences of pharmaceutical compounds in U.S. 
drinking water, in the context of the role of the different point sources of the built water environment, 
the interconnectivity of the built and natural water environments, and to identify opportunities for 
effectively controlling environmental contamination with pharmaceuticals in a sustainable fashion. A 
perspective on this issue is essential, however, for properly managing risks associated with the 
occurrence of pharmaceutical compounds in the built and natural water environment. 
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In this review, we first examine the interplay of the built water environment and the natural water 
environment to inform the management of pharmaceutical pollution; Second, we survey peer-reviewed 
publications for available data on the identity and concentration of pharmaceuticals present in various 
compartments of the water environment, exclusively in the U.S.; Third, we discuss the persistence and 
risk of pharmaceuticals in groundwater and drinking water. Fourth and finally, we propose strategies 
and criteria for minimizing occurrences of pharmaceuticals in drinking water, and in the preceding 
matrices of the natural and built water environment. 
For the purpose of this review, we defined “pharmaceuticals” as prescription and non-prescription 
drugs that are either ingested or topically applied for prevention and/or cure of diseases and injuries. 
Thus, we included antimicrobial compounds that are used heavily in clinics and hospitals; however, we 
excluded other substances such as naturally occurring hormones, flavors and fragrances, cosmetics, 
and personal care products. The literature search was conducted using the Web of Science database, 
using the keyword “pharmaceutical(s)” in various aforementioned matrices of the built and natural 
water environments, including sewage sludge. Only maximum concentrations of the measured 
individual pharmaceuticals were included in this study. Also, we restricted our search to all the studies 
done exclusively in the U.S. 
2. Built and Natural Water Environment 
2.1. General Overview 
The built water environment is a complex network of infrastructure comprising manmade lakes and 
reservoirs, canals, the sewerage and water distribution systems, drinking water treatment plants 
(DWTPs) and wastewater treatment plants (WWTPs), as well as rivers and aquifers reliant on WWTP 
effluent as the principal recharge mechanism. Significant additions to the built water environment 
resulted from the Clean Water Act, which was implemented in 1972 with the objective to “restore and 
maintain the chemical, physical, and biological integrity of the Nation’s waters” [57]. One of the 
provisions of this regulation was to prohibit discharge of toxic pollutants from point sources, including 
domestic households and industrial facilities. The legislation also laid the foundation for the current 
practice of combining industrial and domestic wastewaters before treatment at the WWTP. In this 
context, it is important to note that pretreatment of high-strength industrial waters is widely practiced 
in the U.S. prior to their release into municipal sewer systems. 
Despite these efforts, pharmaceuticals are known to occur in U.S. water resources, which behooves 
us to more closely study and better manage the fate and migration of pharmaceuticals through the 
water environment. Figure 1 shows a number of major components of the built water environment and 
the natural water environment. It identifies important compartments of the built water environment, 
such as sewage systems, WWTPs, DWTPs and the water distribution system, and shows how this 
manmade infrastructure is in communication with multiple components of the natural water 
environment, including surface water (rivers, lakes, oceans, as well as aquifers) and groundwater. Due 
to this connectivity, pharmaceuticals frequently straddle the interface of the built and natural water 
environments, thereby posing potential risks to humans as well as to aquatic and other terrestrial life 
forms that rely on water resources to survive and flourish. 
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Figure 1. Schematic showing inputs of pharmaceuticals to, and the interconnectivity of, 
the natural and built water environment. 
 
The major routes of pharmaceutical administration include enteral (e.g., oral), parenteral  
(e.g., injection), topical (e.g., skin surface), and inhalation. The ingested pharmaceuticals (mainly via 
enteral and parenteral administration) are excreted as un-metabolized or metabolized products, 
whereas the topically applied substances that do not enter the body by absorption also can be washed 
down the drain [33,52]. These pharmaceuticals are combined in the sewer system with black water 
(feces and urine) and gray water (domestic process waters from, e.g., washing, bathing, showering and 
kitchen use) to form raw wastewater or its synonym, sewage (Raw WW or RWW). Expired and 
unwanted (leftover) pharmaceuticals may be flushed down the drain, thereby leading to direct loading 
to wastewater [53]. Another source of pharmaceutical contamination in Raw WW is from the influx of 
waste from pharmaceutical manufacturing companies [50] and healthcare facilities [51].  
Raw WW is conveyed to WWTPs whose primary goal is the removal of pathogens, turbidity, odor, 
color, Biological Oxygen Demand (BOD) and nutrients (primarily nitrogen and phosphorus) through a 
combination of physical, biological and chemical treatment [2]. However, their ability to also remove 
to a significant degree, the Pharmaceuticals and Personal Care Products (PPCPs), and other commodity 
chemicals is widely recognized and has been reviewed both from a mechanistic and quantitative 
perspective [58]. There are two process streams exiting the WWTPs: aqueous flow in the form of 
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treated wastewater (Treated WW or TWW); and the municipal wastewater residuals or sewage sludge, 
which is an unwanted byproduct and that can be converted to so-called biosolids via additional 
treatment processes, including aerobic and/or anaerobic digestion, lime stabilization, and dewatering [59]. 
Treated WW is either reclaimed for land irrigation and farming or discharged into surface waters 
(streams, lakes, rivers, ponds, etc.) to close the water cycle. In coastal settings, biological sewage 
treatment is often omitted, and the effluent of primary treatment is directly discharged into the ocean. 
Pharmaceuticals discharged into surface waters may cause contamination of groundwater in aquifers, 
wells, springs and sumps either via direct leaching into the river bed or following application on land 
in irrigation water [8,11]. 
Pharmaceuticals may also enter surface water and groundwater through leaching of land-based 
pharmaceutical waste and solid waste contaminated with drugs. Major sources are unwanted or 
leftover drugs in domestic solid waste from residential households [52], from the pharmaceutical 
industry [50,60,61], from farm operations that land apply drug-tainted biosolids [62,63], and from 
animal waste that may contain excreted pharmaceuticals and partially metabolized drugs [40,64]. 
Another possible pathway for surface water and groundwater contamination is from leaking sewage 
distribution lines or overflows of combined sewer systems and, less prominent, overflows of sanitary 
sewer systems, both occurring under conditions of heavy rainfall or snowmelt. Although these 
overflows are seasonal/occasional, their impact of contamination can be significant, since the 
discharged sewer may contain untreated pharmaceuticals that are washed directly into surface water 
from where it may infiltrate into groundwater [65–67].  
In the U.S., as in many other countries, groundwater can and is being used directly for consumption 
as drinking water without any treatment, particularly in rural and remote settings [68]. In contrast, 
surface water typically is subject to a multi-barrier treatment train to remove chemical and biological 
contaminants. Ocean water also may serve as a source of drinking water but it undergoes extreme 
treatment in the form of either distillation or reverse osmosis filtration. Raw drinking water (Raw DW 
or RDW) is processed in DWTPs to produce finished drinking water (Finished DW or FDW) that is 
ready for distribution as tap water or bottling, distribution and retail (Figure 1). 
2.2. Occurrence and Distribution of Pharmaceuticals in the Built and Natural Water Environment 
In the following section, we present the number of pharmaceuticals distributed according to their 
highest concentration reported in each of the concentration ranges in various compartments of the built 
and natural water environments (Figure 2). The highest concentration values and names of the 
individual pharmaceuticals occurring in Raw WW, Treated WW, Surface Water, Groundwater, Raw 
DW, and Finished DW are provided Tables S1 to S6, respectively, in the Supplementary Information 
(SI). For simplicity and to avoid redundancy, each individual pharmaceutical measured in each water 
matrix is represented in Figure 2 only once and only in the histogram representing the highest 
concentration range. No pharmaceutical is represented in more than one concentration range within 
each water matrix with the implicit understanding that its presence at sub-maximal concentrations 
constitutes the rule rather than the exception.  
The numbers of pharmaceuticals detected in each of the down gradient matrices include 73 in 
RWW, 92 in TWW, 91 in SW, 33 in GW, 37 in RDW, and 23 in FDW. It is important not to draw 
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potentially misleading conclusions from the data presented in Figure 2 regarding the treatment 
efficiency of infrastructure and the attenuation of drugs in the environment. This could be misleading 
because the maximum concentrations of pharmaceuticals included in this study are from different 
discrete geographical locations within U.S., and the measurement objective was not necessarily to 
investigate the same set of pharmaceuticals in the different water matrices. Nevertheless, occurrence of 
lesser number and lower concentration range of pharmaceuticals in drinking water is noted from a 
human health perspective, regardless of identity or geographical location. 
Figure 2. Number of pharmaceuticals detected in various water matrices of the built water 
environment. Each pharmaceutical is represented only once and shown in the category 
reflecting its respective maximum concentration reported in a given aquatic compartment. 
 
The apparent increase in the total number of pharmaceuticals from RWW (total of 73) to TWW 
(total of 92) is counter-intuitive. Only 62 pharmaceuticals detected were common between these two 
matrices, which may reflect that different sets of pharmaceuticals were measured in the individual 
studies examined here. Other potential explanations for this observation include (i) deconjugation of 
metabolites and release of the parent compounds during treatment; (ii) analytical difficulties that lead 
to higher detection limits in RWW when compared to TWW; (iii) a less comprehensive monitoring of 
RWW compared with TWW; and (iv) the common practice in the analytical laboratory of filtering 
RWW but not necessarily TWW prior to analysis. Since RWW represents a mixture of inputs from 
domestic, municipal and industrial sources entering the WWTP, it is possible that higher than reported 
concentrations of pharmaceuticals may be present in specific process waters prior to mixing and entry 
into WWTPs. Wastewaters discharged by the pharmaceutical industry could constitute a particularly 
strong source term, as revealed in a report by the United States Geological Survey (USGS) [50]. 
Use of filtration during standard sample processing can remove a significant fraction of the 
hydrophobic organic compound mass contained in the sample of interest. A recent study reported that 
up to 86% of the mass of tonalide can be sorbed to filterable material and thus be excluded from 
chemical analyses, due to the common practice of filtering aqueous samples in general and raw sewage 
in particular [69]. Thus, any differences from study to study in both the occurrence and concentration 
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of drugs in a given water matrix may be real or only apparent. Biased data can result from both sample 
processing and analyte detection strategies utilized [69].  
Thirty-three different pharmaceuticals have been reported in U.S. GW and are provided here in 
units of ng/L for maximum concentrations reported: acetaminophen (1890), caffeine (290), 
carbamazepine (420), ciprofloxacin (45), codeine (214), dehydronifedipine (22), diclofenac (46), 
dilantin (22), diltiazem (28), 1,7-dimethylxanthine (57), erythromycin (2380), 17-α-ethinylestradiol (230), 
fluoxetine (56), gemfibrozil (6860), ibuprofen (3110), lincomycin (1900), meprobamate (8.6), 
naproxen (0.7), oestriol (6.4), oestrone (1), oxybenzone (7.5), oxytetracycline (130), pentoxifylline (34), 
primidone (2.8), sulfadimethoxine (130), sulfamerazine (54), sulfamethazine (3600), sulfamethazole (170), 
sulfamethoxazole (1110), sulfathiazole (305), tetracycline (500), triclosan (53), and trimethoprim (18) 
(Figure 2, Table 1). 
In order for a compound to become detectable in groundwater, it either must have passed through 
the wastewater treatment processes prior to injection into the subsurface for aquifer recharge or it must 
have resisted microbial transformation, and sorption to soils and sediments during the slow soil 
infiltration process following application of drug-laden biosolids [11]. Alternatively, compounds may 
enter shallow and deeper groundwater from urination, defecation, sewer overflows, leaking sewage 
distribution lines, and/or through leaching of pharmaceuticals contained in waste resulting from 
agriculture use, such as Concentrated Animal Feeding Operation (CAFO), as indicated in Figure 1.  
Furthermore, twenty-three different pharmaceuticals have been reported in U.S. FDW. Their 
maximum concentrations are provided in units of ng/L in parentheses: acetaminophen (28),  
atenolol (26), caffeine (180.8), carbamazepine (258), codeine (30), cotinine (25), dehydronifedipine (4), 
diazepam (0.33), dilantin (32), erythromycin (1.3), fluoxetine (0.82), gemfibrozil (6.5), genistein (2.9), 
ibuprofen (1350), iopromide (31), lincomycin (4.4), meprobamate (43), naproxen (8), primidone (1.3), 
sulfamethoxazole (20), sulfathiazole (10), triclosan (734), and trimethoprim (1.7) (Figure 2, Table 1)). 
The presence of pharmaceuticals in FDW may be related to multiple factors, including the 
pharmaceuticals’ physical-chemical properties that allowed them to resist general biological, physical 
and chemical transformation processes, specific efficiency and/or overload of the treatment facilities 
(WWTP and DWTP) they passed through, and their respective initial mass loadings [66,70,71].  
Whether long-term risks exist from chronic exposure to these compounds at low levels is a more 
difficult question to answer. Long-term, low-level exposures may involve toxicological mechanisms 
different from those observed in short-term, high-dose studies [71]. Furthermore, future demand for 
drinking water is expected to increase due to population growth and shortening of the water loop. 
Increased reliance on aggressive water reuse already is a key driver of research on contaminants of 
emerging concern (CECs). This notion is supported by the occurrence of pharmaceuticals in TWW  
(n = 92 drugs), SW (n = 91 drugs), GW (n = 33 drugs), and RDW (n = 37 drugs). Although 
generalizations are difficult to formulate, most immediate potential human health risks likely stem 
from elevated levels of pharmaceuticals in FDW, followed by drinking of untreated groundwater, 
which is more common in rural populations. 
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Table 1. Maximum concentrations of pharmaceuticals detected in Groundwater (GW) and 
in Finished Drinking Water (FDW) of the United States. Also shown are the Predicted  
No-Effect Concentration (PNEC) and the calculated Risk Quotient (RQ). 
Pharmaceuticals PNEC (ng/L) GW (ng/L) RQ (GW) FDW (ng/L) RQ (FDW) 
Acetaminophen 
Atenolol 
Caffeine 
Carbamazepine 
Ciprofloxacin 
Codeine 
Cotinine 
Dehydronifedipine 
Diazepam 
Diclofenac 
Dilantin (Phenytoin) 
Diltiazem 
1,7-dimethylxanthine 
Erythromycin 
17-α-ethinylestradiol 
Fluoxetine 
Gemfibrozil 
Genistein 
Ibuprofen 
Iopromide 
Lincomycin 
Meprobamate 
Naproxen 
Oestriol 
Oestrone 
Oxybenzone 
Oxytetracycline 
Pentoxifylline 
Primidone 
Sulfadimethoxine 
Sulfamerazine 
Sulfamethazine 
Sulfamethoxazole 
Sulfathiazole 
Tetracycline 
Triclosan 
Trimethoprim 
1,000 [72] 
3.1 × 105 [73] 
1.0 × 107 [64] 
420 [74]  
5 [75]  
2,900 a 
5,200 a 
15,000 a 
4,300 [76] 
460 [77] 
1,800 a 
920 a 
8,000 a 
20 [77]  
1,800 a 
47 [77] 
780 [77] 
550 a 
1,000 [72] 
460,000 a 
13,000 a 
110,000 a 
640 [77] 
14,000 a 
4,800 a 
3,500 a 
200 [76] 
4,600 a 
4,300 a 
248,000 a 
116,000 a 
1.2 × 106 a 
27 [78] 
5,000 a 
90 [76] 
1,550 [72] 
1,000 [64] 
1,890 [68] 
NA 
290 [68] 
420 [68,79] 
45 [8] 
214 [68] 
NA 
22 [80] 
NA 
46 [79] 
22 [79] 
28 [80] 
57 [80] 
2,380 [81] 
230 [8] 
56 [80] 
6,860 [82] 
NA 
3,110 [80] 
NA 
1,900 [83] 
8.6 [79] 
0.7 [79] 
6.4 [79] 
1 [79] 
7.5 [79] 
139 [84] 
34 [79] 
2.8 [85] 
130 [83] 
54 [81] 
3,600 [83] 
1,110 [80] 
305 [81] 
500 [7] 
53 [8] 
18 [68] 
1.890 
– 
0.01 
1.00 
9.0 
0.07 
– 
<0.01 
– 
0.1 
– 
0.03 
0.007 
119 
0.128 
1.191 
– 
– 
3.11 
– 
0.025 
– 
– 
<0.01 
<0.01 
<0.01 
0.695 
<0.01 
– 
<0.01 
<0.01 
0.001 
41.11 
0.061 
5.6 
0.034 
0.018 
28 [86] 
26 [37] 
180.8 [86] 
258 [87] 
NA 
30 [88] 
25 [87] 
4 [87] 
0.33 [14] 
NA 
32 [37] 
NA 
NA 
1.3 [89] 
NA 
0.82 [14] 
6.5 [90] 
2.9 [37] 
1350 [91] 
31 [89] 
4.4 [86] 
43 [37] 
8 [89] 
NA 
NA 
NA 
NA 
NA 
1.3 [92]  
NA 
NA 
NA 
20 [89] 
10 [88] 
NA 
734 [91] 
1.7 [86] 
0.028 
0.01 
0.01 
0.614 
– 
0.01 
0.01 
0.01 
0.01 
– 
0.018 
– 
– 
0.065 
– 
0.017 
0.008 
0.005 
1.350 
0.01 
0.01 
0.01 
0.013 
– 
– 
– 
– 
– 
0.01 
– 
– 
– 
0.741 
0.002 
– 
0.474 
0.002 
Notes: NA = Not Available; a Calculated = Chronic toxicity concentration (in ng/L) for fish (obtained from 
PBT Profiler [93])/100. 
A comparison of the concentrations of pharmaceuticals occurring in GW and FDW against 
threshold concentrations of pharmaceuticals in drinking water is warranted when evaluating the 
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magnitude of risks posed. Since quality standards are not yet available for pharmaceuticals in drinking 
water, we compared the highest concentrations of pharmaceuticals in GW and FDW against the 
predicted no-effect concentration (PNEC) value that is estimated from standard toxicity  
assays [72,76,94,95]. The result of this comparison is a calculated risk quotient (RQ), which is the ratio 
of the highest concentration of pharmaceuticals divided by the PNEC. We either used the lowest 
PNEC values available in the peer-reviewed literature, or estimated it by dividing the chronic  
(long-term) toxicity value for fish (obtained from PBT Profiler [93]) with an assessment factor of  
100 [95] for extrapolating the test organism’s chronic toxicity to the corresponding anticipated human 
no-effect concentration [72,94,96]. 
Table 1 shows PNEC and RQ values available for all the pharmaceuticals in GW and FDW. In GW, 
acetaminophen, carbamazepine, erythromycin, fluoxetine, ibuprofen, sulfamethoxazole, and tetracycline 
have RQ value > 1, and thus may pose a potential risk to humans, if the respective water is consumed 
without any (point-of-use) treatment. On the other hand, FDW has only ibuprofen with RQ value >1.  
2.3. Pharmaceuticals in Municipal Sludge 
An unwanted byproduct of wastewater treatment is sewage sludge that typically is treated to 
achieve stabilization and enable its application on land as biosolids according to federal and state 
guidelines. Municipal sludge used as fertilizer or soil conditioner is the subject of recent investigations 
as a source of organic pollutants in soils and adjacent aquatic environments [58,97,98]. The high 
organic carbon content of sewage sludge favors preferential sorption and enrichment of hydrophobic 
organic compounds during wastewater treatment process [58,99,100].  
Figure 3 shows the number of pharmaceuticals distributed according to their maximum 
concentration (in units of μg/kg dry weight) reported in each of the concentration ranges in sewage 
sludge (Panel A), and the identity and maximum concentrations of pharmaceuticals occurring in 
>10,000 μg/kg dry weight concentration range (Panel B). The most abundant compounds are the two 
antimicrobial compounds, triclocarban (441,000) and triclosan (133,000). Other major contributors are 
the antibiotics ciprofloxacin (47,500), ofloxacin (58,100), and sulfanilamide (15,600). The 
antihistamine diphenhydramine (22,000) and the pain-reliever ibuprofen (11,900) contribute a lesser 
but still substantial mass fraction. Pharmaceuticals reported in biosolids at maximum concentrations of 
1000 to <10,000 μg/kg include acetaminophen, anhydrotetracycline, azithromycin, caffeine, 
carbamazepine, chlortetracycline, cimetidine, clindamycin, 1,7-dimethylxanthine, doxycycline,  
4-epianhydrotetracycline, 4-epitetracycline, fluoxetine, gemfibrozil, isochlortetracycline, metformin, 
miconazole, minocycline, naproxen, norfloxacin, ranitidine, sarafloxacin, and tetracycline. Maximum 
concentrations between 100 and <1000 μg/kg were reported for anhydrochlortetracycline, clofibric 
acid, codeine, cotinine, demeclocycline, diclofenac, diltiazem, 4-epichlortetracycline, erythromycin 
(total), erythromycin-H2O, 17 alpha-ethinylestradiol, norfluoxetine, estriol, estrone, oxytetracycline, 
paroxetine, salicylic acid, sulfadiazine, sulfamerazine, sulfamethoxazole, thiabendazole, trimethoprim, 
and virginiamycin. Maximum levels in biosolids of 10 to <100 μg/kg were found for aspirin, albuterol, 
clarithromycin, dehydronifedipine, enrofloxacin, 4-epioxytetracycline, ketoprofen, lincomycin, 
lomefloxacin, oxolinic acid, roxithromycin, sulfachloropyridazine, sulfadimethoxine, sulfamethazine, 
sulfathiazole, and sulfisoxazole. At maximum concentrations of 0.1 to <10 μg/kg, only one drug, 
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ormetoprim, was reported to occur in biosolids. The maximum concentration values and names of the 
individual pharmaceuticals occurring in Sewage Sludge are provided Table S7 in the Supplementary 
Information (SI). 
Figure 3. (A) Number of pharmaceuticals detected in sewage sludge. Only maximum 
concentrations of the pharmaceuticals were included and categorized into different 
concentration ranges; (B) Identity and maximum concentrations of pharmaceuticals 
detected in sewage sludge at concentrations exceeding 10,000 μg/kg dry weight. 
 
The accumulation of certain pharmaceuticals by sorption to sewage sludge can aid in the removal 
from the water environment but also can cause problems later on during disposal of these  
materials [8,97]. Today, approximately 50% of U.S. sewage sludge is applied on land as biosolids for 
inexpensive disposal and as a fertilizer or soil conditioner [101]. The application of biosolids laced 
with pharmaceuticals can pose secondary risks to water resources via leaching into groundwater and 
contamination of surface waters from runoff [63,102–105]. 
Additionally, pharmaceuticals contained in land-applied biosolids can directly pose risk to the 
environment and humans. Depending on their physical-chemical properties, pharmaceuticals can be 
strongly sorbed to soil and persist for a long time, or cause toxicity to soil bacteria and other 
microorganisms, thereby adversely impacting soil quality [59]. Furthermore, pharmaceuticals can be 
bioaccumulated into plants and crops that form part of the human diet. For example, bioaccumulation 
has been reported for sulfamethazine on lettuce, potato and corn [106], for chlortetracycline on corn, 
green onions and cabbage [107], and for carbamazepine, sulfamethoxazole, salbutamol, trimethoprim 
on Chinese cabbage (Brassica campestris) [108]. 
3. Sustainable Management of Pharmaceuticals 
Reports of pharmaceuticals in the environment are projected to increase in the future due to increased 
monitoring efforts, a shortening of the water cycle, increased drug consumption, and the availability of 
advanced measurement technologies for trace analysis of pharmaceuticals in complex matrices. These 
projections demand sustainable management of pharmaceuticals in our water environment. 
For example, progress has been made toward the use of advanced processing techniques that may 
minimize the occurrence of pharmaceuticals in drinking water. These advanced treatment techniques 
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employ chemical [37], biological [36], and physical processes [34]. Chemical processes using 
advanced oxidation [109,110] and ozonation [39] have been shown to improve removal efficiency 
when used individually or in sequence [37,38,111,112]. For example, triclosan, ibuprofen, 
sulfamethoxazole, trimethoprim, naproxen, carbamazepine, phenytoin, diazepam, caffeine and 
fluoxetine removal efficiencies were improved by >70% through ozonation at a dose of 2.5 mg/L [37]. 
Additionally, progress has been made towards developing “green” chemistry approaches, for example, 
using Fe-TAML catalysts for purifying environmental waters [113]. 
The improved removal efficiency mentioned above, however, needs to be further investigated in 
order to assess whether the treatment technique will result in complete degradation of the 
pharmaceutical compounds (the safe and desired end result of any treatment process), or whether it 
transformed the pharmaceuticals into other products that may or may not be safe, when occurring both 
in isolation or in a mixture.  
Besides improving the efficiency of DWTP, controlling important point sources of pharmaceuticals 
ought to be a priority in minimizing water and soil contamination. Source control of pharmaceutical 
contamination begins with proper disposal of pharmaceutical waste streams, as well as expired and 
leftover pharmaceuticals. Daughton and colleagues have thoroughly reviewed the reasons for 
accumulation of pharmaceuticals and repercussions of disposing leftover pharmaceuticals into sewage 
and solid waste [1,15,52,53,114]. The recommendation from these reviews is simple: do not throw 
unused or leftover pharmaceuticals in the toilet or flush them down the drain. Proper disposal methods 
should be practiced, for example, dropping off pharmaceuticals at local facilities that collect them. 
Environmental occurrence of pharmaceuticals is not really a new problem but one that had been 
concealed for decades due to the lack of both suitable analytical techniques and financial resources to 
enable monitoring using available methods. Detection methods have improved substantially in the past 
decade and will have to be revised continuously in the future to include new pharmaceuticals entering 
the market. Additionally, pharmaceuticals should be routinely monitored in environmental compartments 
and process flows that are in communication with drinking water resources (Figure 1) for early 
detection of potential hazards.  
In addition to continued efforts to improve the removal efficiencies of WWTPs and DWTPs, 
pharmaceutical industries and academic research institutions may harness new technologies to design 
“green pharmaceuticals” [115]. Next generation “green pharmaceuticals” ideally will be designed to 
undergo removal and destruction in sewage and drinking water treatment works, while maintaining the 
therapeutic qualities of their contemporary counterparts in vivo in the target organism (i.e., humans  
and animals). 
Furthermore, municipalities and academic institutions may engage in public education for proper 
use and disposal of pharmaceuticals in partnership with government agencies. Regulating agencies 
may take a more active role in implementing policies to curtail excessive application of 
pharmaceuticals in agribusiness, require risk assessment of new pharmaceuticals before market launch, 
and promote education on managing chemicals in a sustainable manner. 
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4. Summary and Conclusions 
Pharmaceuticals are subject to repeated transfer between the built water environment and the 
natural water environment. Typical cycles for polluting drugs include excretion or disposal into 
wastewater, incomplete removal during sewage treatment and entry of attenuated drug quantities into 
natural surface waters and terrestrial environments via treated WW and land application of biosolids. 
Reentry of drugs from the natural environment into the built water environment occurs during uptake 
of source water for the water supply. Removal of drugs during DW treatment is incomplete, causing 
the occurrence of ng/L to μg/L concentrations of certain pharmaceuticals in finished DW. Population 
growth and a shortening of the natural water cycle likely will lead to an increase in trace levels of 
drugs in DW unless pharmaceutical pollution will be managed more proactively in the future. 
Risk reduction opportunities and continuing research needs exist in the areas of: 
• Long-term effects of low-level pharmaceutical contamination on human health; 
• Short- and long-term effects of pharmaceutical contamination on non-target organisms; 
• Comprehensive evaluations of treatment works (DWTPs and WWTPs) to identify infrastructure 
that improves the removal efficiencies of pharmaceuticals, and minimizes associated costs; 
• Enhanced monitoring of pharmaceuticals in the built water environment to facilitate accurate 
evaluation of removal efficiencies of treatment works and to identify all possible avenues by 
which pharmaceuticals enter the natural water environment (including sewer overflows, 
leachates from solid waste, and biosolids runoff); 
• More targeted monitoring of pharmaceuticals that are toxic to indicator organisms, are 
produced in high-volume, and possess persistent physico-chemical properties (i.e., long 
environmental half-life); 
• Design of pharmaceuticals that are susceptible to transformation (or degradation) by treatment 
works and/or natural processes (e.g., photolysis); 
• Identification and elimination of high-strength wastewaters from the pharmaceutical industry; 
• Partnerships between academic institutions, pharmaceutical industries, and government to 
promote public education for proper use and disposal of pharmaceuticals. 
Given the importance of preserving the quality of natural waters and the security of the drinking 
water supply, it may be desirable to provide additional funding mechanisms to support these ongoing 
and suggested activities (e.g., through leveling of a modest tax on pharmaceutical sales). 
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